# Minghui Pharmaceutical (Hangzhou) Ltd trials: 20 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 20 trials with Minghui Pharmaceutical (Hangzhou) Ltd as lead sponsor, 13 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Minghui Pharmaceutical (Hangzhou) Ltd: 20 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/minghui-pharmaceutical-hangzhou-ltd

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 20
- Recruiting or not yet: 13
- Read on: November 19, 2026

## Trials

The 20 newest of 20, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| July 6, 2026 | NCT07682506 | A Phase III Clinical Study to Evaluate the Efficacy and Safety of MH004 Ointment in Non-segmental Vitiligo | Minghui Pharmaceutical (Hangzhou) Ltd | Phase 3 | Recruiting | Vitiligo | 405 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07682506) |
| June 2, 2026 | NCT07622121 | Treatment of Chronic Thyroid Eye Disease With MHB018A | Minghui Pharmaceutical (Hangzhou) Ltd | Phase 3 | Recruiting | Thyroid Eye Disease, TED | 135 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07622121) |
| June 2, 2026 | NCT07622108 | Treatment of Active Thyroid Eye Disease With MHB018A in a Randomized, Placebo-Controlled Study | Minghui Pharmaceutical (Hangzhou) Ltd | Phase 3 | Recruiting | Thyroid Eye Disease, TED | 84 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07622108) |
| June 2, 2026 | NCT07620405 | Open-Label Extension Study of MHB018A in Patients With Thyroid Eye Disease | Minghui Pharmaceutical (Hangzhou) Ltd | Phase 3 | Not yet recruiting | Thyroid Eye Disease (TED) | 219 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07620405) |
| January 8, 2026 | NCT07326488 | A Study of MHB009C in Patients With Advanced Solid Tumors | Minghui Pharmaceutical (Hangzhou) Ltd | Phase 1/2 | Recruiting | Advanced Malignant Solid Tumor | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07326488) |
| December 3, 2025 | NCT07262476 | Open-Label Extension Study of MHB018A in Subjects With Thyroid Eye Disease | Minghui Pharmaceutical (Hangzhou) Ltd | Phase 3 | Recruiting | Thyroid Eye Disease (TED) | 258 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07262476) |
| December 2, 2025 | NCT07257185 | MHB018A Treatment in Patients With Chronic Thyroid Eye Disease | Minghui Pharmaceutical (Hangzhou) Ltd | Phase 3 | Active not recruiting | Thyroid Eye Disease (TED) | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07257185) |
| November 17, 2025 | NCT07229599 | A Study of MHB036C Combined With Anti-tumor Therapies in Patients With Advanced Lung Cancer | Minghui Pharmaceutical (Hangzhou) Ltd | Phase 1/2 | Recruiting | Advanced Lung Cancer | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07229599) |
| September 25, 2025 | NCT07192120 | A Study of MHB048C in Patients With Advanced Solid Tumors | Minghui Pharmaceutical (Hangzhou) Ltd | Phase 1/2 | Recruiting | mCRPC (Metastatic Castration-resistant Prostate Cancer), Advanced Malignant Solid Tumor | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07192120) |
| September 25, 2025 | NCT07192107 | A Study of MHB042C in Patients With Advanced Solid Tumors | Minghui Pharmaceutical (Hangzhou) Ltd | Phase 1/2 | Recruiting | Advanced Malignant Solid Tumor | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07192107) |
| September 22, 2025 | NCT07185282 | A Phase 3 Study of MH004 Ointment in Patients With Mild to Moderate Atopic Dermatitis | Minghui Pharmaceutical (Hangzhou) Ltd | Phase 3 | Completed | Atopic Dermatitis (AD) | 375 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07185282) |
| September 19, 2025 | NCT07182864 | MH004 Ointment in Healthy Adult Volunteers and Participants With Mild to Moderate Atopic Dermatitis | Minghui Pharmaceutical (Hangzhou) Ltd | Phase 1/2 | Completed | Atopic Dermatitis (AD) | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07182864) |
| September 18, 2025 | NCT07181187 | Phase II Clinical Trial of MH004 Ointment in Patients With Non-segmental Vitiligo | Minghui Pharmaceutical (Hangzhou) Ltd | Phase 2 | Completed | Vitiligo | 156 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07181187) |
| August 19, 2025 | NCT07130383 | A Study of MHB036C Combined With MHB039A in Patients With Advanced Breast Cancer or Other Advanced Malignant Solid Tumors | Minghui Pharmaceutical (Hangzhou) Ltd | Phase 2 | Recruiting | Advanced Breast Cancer, Advanced Malignant Solid Tumor | 210 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07130383) |
| August 17, 2025 | NCT07126665 | A Study of MHB088C Combined With MHB039A in Patients With Advanced Malignant Solid Tumors | Minghui Pharmaceutical (Hangzhou) Ltd | Phase 1/2 | Recruiting | Advanced Malignant Solid Tumor | 116 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07126665) |
| July 1, 2025 | NCT07045454 | A Study of MHB118C Injection in Patients With Advanced Solid Tumors | Minghui Pharmaceutical (Hangzhou) Ltd | Phase 1 | Recruiting | Advanced Malignant Solid Tumor | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07045454) |
| May 25, 2025 | NCT06989918 | MHB018A Treatment in Patients With Active Thyroid Eye Disease | Minghui Pharmaceutical (Hangzhou) Ltd | Phase 3 | Active not recruiting | Thyroid Associated Ophthalmopathies | 108 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06989918) |
| May 22, 2025 | NCT06985355 | A Study of MHB046C Injection in Patients With Advanced Solid Tumors | Minghui Pharmaceutical (Hangzhou) Ltd | Phase 1/2 | Recruiting | Advanced Solid Cancer | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06985355) |
| April 18, 2024 | NCT06373406 | A Study of MHB036C for Advanced Solid Tumor | Minghui Pharmaceutical (Hangzhou) Ltd | Phase 1/2 | Active not recruiting | Advanced Solid Tumor | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06373406) |
| April 3, 2024 | NCT06345482 | A Study of MHB039A for Advanced Solid Tumor | Minghui Pharmaceutical (Hangzhou) Ltd | Phase 1/2 | Active not recruiting | Advanced Solid Tumor | 196 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06345482) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 1 |
| Phase 1/2 | 9 |
| Phase 2 | 2 |
| Phase 3 | 8 |

## By status

| Status | Trials |
| --- | --- |
| Recruiting | 12 |
| Active not recruiting | 4 |
| Completed | 3 |
| Not yet recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Graves Ophthalmopathy | 6 |
| Dermatitis, Atopic | 2 |
| Vitiligo | 2 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Pan Asian restaurants in the United States](https://specstream.ai/data/businesses/pan-asian-restaurants/united-states)
- [Syrian restaurants in the United States](https://specstream.ai/data/businesses/syrian-restaurants/united-states)
- [B2B medical support companies in the United States](https://specstream.ai/data/businesses/b2b-medical-support-companies/united-states)
- [Distilleries in the United States](https://specstream.ai/data/businesses/distilleries/united-states)
- [Hyperbaric medicine centers in the United States](https://specstream.ai/data/businesses/hyperbaric-medicine-centers/united-states)
